m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05304
 [1]
Non-coding RNA miR-21-5p METTL3  lncRNA       miRNA   circRNA Direct Inhibition m6A modification WIF1 WIF1 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Wnt inhibitory factor 1 (WIF1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-21-5p microRNA View Details
Regulated Target Methyltransferase-like protein 3 (METTL3) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary hsa-miR-21-5p inhibited the METTL3-mediated m6A modification and mRNA stability of Wnt inhibitory factor 1 (WIF1), thereby facilitating the proliferation, invasion, and migration of Ect-ESCs.
Responsed Disease Endometriosis ICD-11: GA10
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
GA10: Endometriosis 32 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Elagolix sodium Approved [2]
Synonyms
Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336
    Click to Show/Hide
External Link
CID: 24785956
TTD: D0VG7Y
 Compound Name Histrelin Approved [3]
Synonyms
Supprelin (TN)
    Click to Show/Hide
External Link
CID: 25077993
TTD: D0O7DG
 Compound Name Relugolix Phase 3 [4]
Synonyms
737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917
    Click to Show/Hide
External Link
CID: 10348973
TTD: D0F2WP
DrugBank: DB11853
 Compound Name Naproxen Approved [5]
Synonyms
22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex
    Click to Show/Hide
External Link
CID: 156391
TTD: D0DJ1B
DrugBank: DB00788
 Compound Name Nafarelin Approved [6]
Synonyms
Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)
    Click to Show/Hide
External Link
CID: 25077405
TTD: D08WYM
DrugBank: DB00666
 Compound Name Oestradiol valerate and dienogest Approved [7]
Synonyms
Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)
    Click to Show/Hide
External Link
CID: 68861
TTD: D04CBI
DrugBank: DB09123
 Compound Name TZTX-001 Phase 3 [8]
Synonyms
Teverelix LA; TX 12-001-HR
    Click to Show/Hide
External Link
TTD: D0IC7A
 Compound Name Nestorone Phase 3 [9]
Synonyms
Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux
    Click to Show/Hide
External Link
CID: 108059
TTD: D02HUB
DrugBank: DB14583
 Compound Name Telapristone Phase 2 [10]
Synonyms
Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11
    Click to Show/Hide
External Link
CID: 20761503
TTD: D0U8AS
 Compound Name F-8-IL-10 fusion protein Phase 2 [11]
Synonyms
Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen
    Click to Show/Hide
External Link
TTD: D0T4KG
 Compound Name PGL-2 Phase 2 [12]
External Link
TTD: D0I3RN
 Compound Name BAY 98-7196 Phase 2 [13]
External Link
TTD: D0E7VY
 Compound Name KLH-2109 Phase 2 [14]
External Link
CID: 16656889
TTD: D08FKH
 Compound Name Vilaprisan Phase 2 [15]
Synonyms
UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-
    Click to Show/Hide
External Link
CID: 50915138
TTD: D07YGK
DrugBank: DB11971
 Compound Name PGL-2001 Phase 2 [16]
Synonyms
Steroid sulfatase inhibitor (endometriosis), PregLem
    Click to Show/Hide
External Link
CID: 6918339
TTD: D04ZND
DrugBank: DB06597
 Compound Name BGS-649 Phase 2 [17]
External Link
TTD: D02XMD
 Compound Name ASP-1707 Phase 2 [18]
External Link
TTD: D02ROU
 Compound Name BAY 1817080 Phase 1 [19]
Synonyms
Eliapixant
    Click to Show/Hide
External Link
TTD: DF0PI8
 Compound Name Alfa-interferon Phase 1 [20]
External Link
TTD: D0SX9C
 Compound Name PF-4418948 Phase 1 [21]
Synonyms
PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer
    Click to Show/Hide
External Link
CID: 25114442
TTD: D0S5EF
DrugBank: DB12024
 Compound Name BAY-1817080 Phase 1 [22]
External Link
TTD: D0NF1D
 Compound Name PF-2413873 Phase 1 [23]
Synonyms
PF-02413873
    Click to Show/Hide
External Link
CID: 16662425
TTD: D0K2HA
 Compound Name BAY 1026153 Phase 1 [24]
External Link
TTD: D0FJ0W
 Compound Name PMID27215781-Compound-28 Patented [25]
External Link
TTD: D03YAA
 Compound Name Asoprisnil Discontinued in Phase 3 [26]
Synonyms
J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one
    Click to Show/Hide
External Link
CID: 9577221
TTD: D0W5RL
DrugBank: DB06680
 Compound Name FP-1096 Discontinued in Phase 3 [27]
External Link
TTD: D0K8MQ
 Compound Name ASP-0265 Terminated [28]
External Link
TTD: D0J3PS
 Compound Name NS398 Terminated [29]
Synonyms
ns-398; 123653-11-2; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942
    Click to Show/Hide
External Link
CID: 4553
TTD: D09BKE
DrugBank: DB14060
 Compound Name LHRH Investigative [30]
Synonyms
SCHEMBL7378993
    Click to Show/Hide
External Link
CID: 36523
TTD: D0V6KF
DrugBank: DB00644
 Compound Name PF-02367982 Investigative [31]
Synonyms
CHEMBL1083754; BDBM50318934
    Click to Show/Hide
External Link
CID: 11964844
TTD: D0H2MF
 Compound Name Recombinant human CC10 Investigative [32]
Synonyms
Claragen-WH; Recombinant human CC10 (intravaginal, endometriosis/infertility); Recombinant human CC10 (intravaginal, endometriosis/infertility), Clarassance; Uteroglobin (intravaginal, endometriosis/infertility), Clarassance
    Click to Show/Hide
External Link
TTD: D05RZJ
 Compound Name DXL-1215 Investigative [32]
Synonyms
Monoclonal antibody (endometriosis), InNexus
    Click to Show/Hide
External Link
TTD: D01UBV
References
Ref 1 METTL3 is aberrantly expressed in endometriosis and suppresses proliferation, invasion, and migration of endometrial stromal cells. Kaohsiung J Med Sci. 2023 Mar;39(3):266-277. doi: 10.1002/kjm2.12626. Epub 2022 Dec 22.
Ref 2 2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3884).
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. doi: 10.1517/13543784.17.8.1187.
Ref 6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3902).
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7654).
Ref 8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038089)
Ref 9 ClinicalTrials.gov (NCT00455156) Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring. U.S. National Institutes of Health.
Ref 10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014404)
Ref 11 ClinicalTrials.gov (NCT02270632) A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 Dekavil) in Patients With Active RA Receiving MTX. U.S. National Institutes of Health.
Ref 12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026648)
Ref 13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040286)
Ref 14 ClinicalTrials.gov (NCT01533532) A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2). U.S. National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT02465814) Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids.
Ref 16 ClinicalTrials.gov (NCT01631981) PGL2001 Proof of Concept Study in Symptomatic Endometriosis. U.S. National Institutes of Health.
Ref 17 ClinicalTrials.gov (NCT01190475) BGS649 Monotherapy in Moderate to Severe Endometriosis Patients. U.S. National Institutes of Health.
Ref 18 ClinicalTrials.gov (NCT01767090) A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain. U.S. National Institutes ofHealth.
Ref 19 ClinicalTrials.gov (NCT04471337) Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function. U.S. National Institutes of Health.
Ref 20 A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Med Pediatr Oncol. 1991;19(4):276-82.
Ref 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5817).
Ref 22 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. doi: 10.1038/s41573-019-0013-8.
Ref 23 ClinicalTrials.gov (NCT00800618) A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women. U.S. National Institutes of Health.
Ref 24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035640)
Ref 25 Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
Ref 26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2883).
Ref 27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018823)
Ref 28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028953)
Ref 29 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002344)
Ref 30 Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem. 1998 Oct 22;41(22):4190-5.
Ref 31 Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6.
Ref 32 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.